SlideShare a Scribd company logo
1 of 19
Analysis of Prognostic Factors Influencing the Survival of Patients with Relapsed Follicular Lymphoma M.V.LOMONOSOV  MOSCOW STATE UNIVERSITY FAULTY OF BASIC MEDICINE Presented by: Dr.Zaw Htet Scientific supervisors: Prof.Dr.B.I.Polikov, Dr.D.A.Bykov Moscow,2010
Introduction ,[object Object],[object Object],[object Object],[object Object],[object Object]
Prognosis ,[object Object],[object Object]
Purpose of Study ,[object Object]
Main Tasks of Study ,[object Object],[object Object]
Patients and Methods ,[object Object],151 69 (46%) 60 (40%) 21 (14%) 32 (47%) 37 (64%) 69 Complete Response Partial Response Undetermined Disease Progression (median follow up: 4.5 yrs) Median age: 56 yrs, 36 males, 33 females
Main Characteristics of Patients at diagnosis and at relapse (n=69)
Prognostic factors for survival from progression(SFP) in patients with follicular lymphoma at relapse : Results of univariate analysis (n=69) Variable No. of Patients Mortality (%) 5-year SFP P value Stage at diagnosis I-II III-IV Age <60 years ≥ 60 years Bulky disease No Yes ECOG 0-1 ≥ 2 Serum LDH  <450 U/L ≥ 450 U/L Bone marrow involvement No Yes 11 61 42 30 56 7 57 8 38 10 18 15 14 53 41 54 35 89 37 90 27 67 17 53 82 42 60 28 54 22 53 11 56 44 81 23 0.02 0.07 0.007 0.0002 0.015 0.002
Continued: Variable No. of patients Mortality (%) 5-year SFP P value Stage at relapse I-II III-IV IPI Low  Inter/High  Duration of response <2 years  ≥ 2 years Transformation No  Yes Initial Response CR PR Response to salavage therapy CR PR NR 22 44 38 28 41 31 28 7 31 38 26 22 15 26 51 25 66 55 36 33 33 44 49 26 48 90 68 34 72 13 33 63 63 62 44 48 57 59 0 0.003 <0.0001 0.012 NS NS <0.0001
Multivariate analysis ,[object Object],[object Object],[object Object]
[object Object]
5-years SFP according to response duration(RD) to first line therapy
5-years SFP according to performance status (ECOG) and response duration(RD)
5-years SFP according to performance status(ECOG) and response duration (RD)
Cause-specific SFP ,[object Object],[object Object]
Cause-specific survival from progression
Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object]
 

More Related Content

What's hot

High Risk Lymphoma
High Risk LymphomaHigh Risk Lymphoma
High Risk Lymphomaspa718
 
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseMolecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseSystemic JIA Foundation
 
Oncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondiOncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondiKesho Conference
 
Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever ijac journal
 
Advancing age in liver transplant recipients
Advancing age in liver transplant recipientsAdvancing age in liver transplant recipients
Advancing age in liver transplant recipientshr77
 
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
Abdominal Pain as Initial Presentation of Lung AdenocarcinomaAbdominal Pain as Initial Presentation of Lung Adenocarcinoma
Abdominal Pain as Initial Presentation of Lung Adenocarcinomaasclepiuspdfs
 
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...The Third International Consensus Definitions for Sepsis and Septic Shock (Se...
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...Willian Rojas
 
Ash 2020 Presentations MPN AN dr Claire Harrison
Ash 2020 Presentations MPN AN  dr Claire Harrison Ash 2020 Presentations MPN AN  dr Claire Harrison
Ash 2020 Presentations MPN AN dr Claire Harrison NatasaHace
 
Cerebrovascular stroke recurrence among critically ill patients (2)
Cerebrovascular stroke recurrence among critically ill patients (2)Cerebrovascular stroke recurrence among critically ill patients (2)
Cerebrovascular stroke recurrence among critically ill patients (2)Alexander Decker
 
Advancing Dialysis - Symptoms During Dialysis
Advancing Dialysis - Symptoms During DialysisAdvancing Dialysis - Symptoms During Dialysis
Advancing Dialysis - Symptoms During Dialysisnxstage
 
Realce tardio CRM en Miocardiopatia Hipertrofica
Realce tardio CRM en Miocardiopatia HipertroficaRealce tardio CRM en Miocardiopatia Hipertrofica
Realce tardio CRM en Miocardiopatia HipertroficaAdolfo Aliaga Quezada
 
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...Imhotep Virtual Medical School
 
7 Things to Know about Non-Small Cell Lung Cancer
7 Things to Know about Non-Small Cell Lung Cancer7 Things to Know about Non-Small Cell Lung Cancer
7 Things to Know about Non-Small Cell Lung CancerZeena Nackerdien
 
BMJ Open-2016-Datta-
BMJ Open-2016-Datta-BMJ Open-2016-Datta-
BMJ Open-2016-Datta-Tracey Mare
 

What's hot (18)

Hodgkin’s lymphoma
Hodgkin’s lymphomaHodgkin’s lymphoma
Hodgkin’s lymphoma
 
High Risk Lymphoma
High Risk LymphomaHigh Risk Lymphoma
High Risk Lymphoma
 
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseMolecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
 
Oncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondiOncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondi
 
Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever
 
Advancing age in liver transplant recipients
Advancing age in liver transplant recipientsAdvancing age in liver transplant recipients
Advancing age in liver transplant recipients
 
Truvada kaletra o maraviroc PrEp
Truvada kaletra o maraviroc PrEpTruvada kaletra o maraviroc PrEp
Truvada kaletra o maraviroc PrEp
 
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
Abdominal Pain as Initial Presentation of Lung AdenocarcinomaAbdominal Pain as Initial Presentation of Lung Adenocarcinoma
Abdominal Pain as Initial Presentation of Lung Adenocarcinoma
 
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...The Third International Consensus Definitions for Sepsis and Septic Shock (Se...
The Third International Consensus Definitions for Sepsis and Septic Shock (Se...
 
Ash 2020 Presentations MPN AN dr Claire Harrison
Ash 2020 Presentations MPN AN  dr Claire Harrison Ash 2020 Presentations MPN AN  dr Claire Harrison
Ash 2020 Presentations MPN AN dr Claire Harrison
 
Cerebrovascular stroke recurrence among critically ill patients (2)
Cerebrovascular stroke recurrence among critically ill patients (2)Cerebrovascular stroke recurrence among critically ill patients (2)
Cerebrovascular stroke recurrence among critically ill patients (2)
 
Advancing Dialysis - Symptoms During Dialysis
Advancing Dialysis - Symptoms During DialysisAdvancing Dialysis - Symptoms During Dialysis
Advancing Dialysis - Symptoms During Dialysis
 
SEPSIS Y SHOCK SEPTICO
SEPSIS Y SHOCK SEPTICOSEPSIS Y SHOCK SEPTICO
SEPSIS Y SHOCK SEPTICO
 
Realce tardio CRM en Miocardiopatia Hipertrofica
Realce tardio CRM en Miocardiopatia HipertroficaRealce tardio CRM en Miocardiopatia Hipertrofica
Realce tardio CRM en Miocardiopatia Hipertrofica
 
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...
Make the Dx_ A Case-based Intro to Select Cardiovascular and Respiratory Dise...
 
7 Things to Know about Non-Small Cell Lung Cancer
7 Things to Know about Non-Small Cell Lung Cancer7 Things to Know about Non-Small Cell Lung Cancer
7 Things to Know about Non-Small Cell Lung Cancer
 
Lra lancet
Lra lancetLra lancet
Lra lancet
 
BMJ Open-2016-Datta-
BMJ Open-2016-Datta-BMJ Open-2016-Datta-
BMJ Open-2016-Datta-
 

Viewers also liked

Personas with Personality
Personas with PersonalityPersonas with Personality
Personas with PersonalityBrightEdge
 
PPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarPPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarBrightEdge
 
Tanl power point
Tanl power pointTanl power point
Tanl power pointzawhtet1984
 

Viewers also liked (7)

Personas with Personality
Personas with PersonalityPersonas with Personality
Personas with Personality
 
Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 
Kyaw thura zaw
Kyaw thura zawKyaw thura zaw
Kyaw thura zaw
 
Sithu ko
Sithu koSithu ko
Sithu ko
 
PPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin WebinarPPC Attribution: A Portent & Hanapin Webinar
PPC Attribution: A Portent & Hanapin Webinar
 
Aung thiha soe
Aung thiha soeAung thiha soe
Aung thiha soe
 
Tanl power point
Tanl power pointTanl power point
Tanl power point
 

Similar to Zaw htet

02 ptcl ylk
02 ptcl  ylk02 ptcl  ylk
02 ptcl ylkspa718
 
Mantle Cell Lymphoma PPT.pptx
Mantle Cell Lymphoma PPT.pptxMantle Cell Lymphoma PPT.pptx
Mantle Cell Lymphoma PPT.pptxKunal Chhattani
 
Pros and cons in surveillance imaging in lymphoma
Pros and cons in surveillance imaging in lymphomaPros and cons in surveillance imaging in lymphoma
Pros and cons in surveillance imaging in lymphomasummer elmorshidy
 
13045 2017 article_455
13045 2017 article_45513045 2017 article_455
13045 2017 article_455beatriz9911
 
Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphomafondas vakalis
 
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...Gianfranco Tammaro
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...eshaasini
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...semualkaira
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...semualkaira
 
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsLLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsEuropean School of Oncology
 
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...European School of Oncology
 
Cco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slidesCco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slidesAdonis Guancia
 
Order a20171110 83
Order a20171110 83Order a20171110 83
Order a20171110 83Thomas Ndalo
 
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...CrimsonpublishersCancer
 
Comparative Study of Hscrp in Chronic Kidney Disease
Comparative Study of Hscrp in Chronic Kidney DiseaseComparative Study of Hscrp in Chronic Kidney Disease
Comparative Study of Hscrp in Chronic Kidney Diseaseiosrphr_editor
 
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...European School of Oncology
 
Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.spa718
 

Similar to Zaw htet (20)

02 ptcl ylk
02 ptcl  ylk02 ptcl  ylk
02 ptcl ylk
 
Mantle Cell Lymphoma PPT.pptx
Mantle Cell Lymphoma PPT.pptxMantle Cell Lymphoma PPT.pptx
Mantle Cell Lymphoma PPT.pptx
 
Pros and cons in surveillance imaging in lymphoma
Pros and cons in surveillance imaging in lymphomaPros and cons in surveillance imaging in lymphoma
Pros and cons in surveillance imaging in lymphoma
 
13045 2017 article_455
13045 2017 article_45513045 2017 article_455
13045 2017 article_455
 
Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphoma
 
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
 
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
Relevant Features and Treatment Options of DLBCL Patients with Late Relapse A...
 
Blood cancer 19oct
Blood cancer 19octBlood cancer 19oct
Blood cancer 19oct
 
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsLLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
 
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...
Rare Solid Cancers: An Introduction - Slide 14 - E. Baudin - Neuroendocrine t...
 
Follicular Lymphoma [autosaved]
Follicular Lymphoma [autosaved]Follicular Lymphoma [autosaved]
Follicular Lymphoma [autosaved]
 
Cco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slidesCco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slides
 
Order a20171110 83
Order a20171110 83Order a20171110 83
Order a20171110 83
 
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...
The Immunosuppressive Significance of Lactate Dehydrogenase (LDH) Blood Level...
 
The Spectrum of Histopathological Patterns in Diabetic Kidney Disease in East...
The Spectrum of Histopathological Patterns in Diabetic Kidney Disease in East...The Spectrum of Histopathological Patterns in Diabetic Kidney Disease in East...
The Spectrum of Histopathological Patterns in Diabetic Kidney Disease in East...
 
Comparative Study of Hscrp in Chronic Kidney Disease
Comparative Study of Hscrp in Chronic Kidney DiseaseComparative Study of Hscrp in Chronic Kidney Disease
Comparative Study of Hscrp in Chronic Kidney Disease
 
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
 
Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.
 

More from zawhtet1984

Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)zawhtet1984
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihazawhtet1984
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)zawhtet1984
 

More from zawhtet1984 (6)

Yehlaingbwar
YehlaingbwarYehlaingbwar
Yehlaingbwar
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
Chan myae htut
Chan myae htutChan myae htut
Chan myae htut
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
 

Recently uploaded

Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxNikitaBankoti2
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docxPoojaSen20
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701bronxfugly43
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfChris Hunter
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Shubhangi Sonawane
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 

Recently uploaded (20)

Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptx
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 

Zaw htet

  • 1. Analysis of Prognostic Factors Influencing the Survival of Patients with Relapsed Follicular Lymphoma M.V.LOMONOSOV MOSCOW STATE UNIVERSITY FAULTY OF BASIC MEDICINE Presented by: Dr.Zaw Htet Scientific supervisors: Prof.Dr.B.I.Polikov, Dr.D.A.Bykov Moscow,2010
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Main Characteristics of Patients at diagnosis and at relapse (n=69)
  • 8. Prognostic factors for survival from progression(SFP) in patients with follicular lymphoma at relapse : Results of univariate analysis (n=69) Variable No. of Patients Mortality (%) 5-year SFP P value Stage at diagnosis I-II III-IV Age <60 years ≥ 60 years Bulky disease No Yes ECOG 0-1 ≥ 2 Serum LDH <450 U/L ≥ 450 U/L Bone marrow involvement No Yes 11 61 42 30 56 7 57 8 38 10 18 15 14 53 41 54 35 89 37 90 27 67 17 53 82 42 60 28 54 22 53 11 56 44 81 23 0.02 0.07 0.007 0.0002 0.015 0.002
  • 9. Continued: Variable No. of patients Mortality (%) 5-year SFP P value Stage at relapse I-II III-IV IPI Low Inter/High Duration of response <2 years ≥ 2 years Transformation No Yes Initial Response CR PR Response to salavage therapy CR PR NR 22 44 38 28 41 31 28 7 31 38 26 22 15 26 51 25 66 55 36 33 33 44 49 26 48 90 68 34 72 13 33 63 63 62 44 48 57 59 0 0.003 <0.0001 0.012 NS NS <0.0001
  • 10.
  • 11.
  • 12. 5-years SFP according to response duration(RD) to first line therapy
  • 13. 5-years SFP according to performance status (ECOG) and response duration(RD)
  • 14. 5-years SFP according to performance status(ECOG) and response duration (RD)
  • 15.
  • 17.
  • 18.
  • 19.